Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | DDX3X | O00571 | 1/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11756426 | 0.92 | MEN1 (0.80) | MEN1KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL30555757 | 0.89 | MEN1 (0.72) | MEN1KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL30020550 | 0.89 | MEN1 (0.72) | MEN1KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL9167675 | 0.89 | MEN1 (0.72) | MEN1KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL4749088 | 0.88 | L3MBTL1 (0.71) | MEN1KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL5213509 | 0.88 | CYP1A2 (0.78) | MEN1KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL30957465 | 0.88 | CYP1A2 (0.78) | MEN1KMT2AL3MBTL1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL27290577 | 0.87 | CYP1A2 (0.76) | MEN1KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL32664264 | 0.87 | L3MBTL1 (0.82) | MEN1KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL26496469 | 0.87 | L3MBTL1 (0.82) | MEN1KMT2AL3MBTL1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20130331411-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2013-12-12 | — | — | US | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| EP-0425345-B1 | Keratinic fibres dyeing process with amino-indoles, composition and use devices | OREAL (FR) | 1994-09-14 | — | — | EP | disclosed |
| US-5254135-A | Applying indole dye, developing with oxidizing system | L'OREAL (FR) | 1993-10-19 | — | — | US | disclosed |
| CN-1051669-A | With the method for amino indole dyeing keratinous fibres, compositions and facilities and equipments | OREAL (FR) | 1991-05-29 | — | — | CN | disclosed |
| EP-0425345-A1 | Keratinic fibres dyeing process with amino-indoles, composition and use devices | L'OREAL (FR) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331411-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | MEN1 1236/4885KMT2A 3844/4885L3MBTL1 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.